Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

Inclusion Criteria: * SARS-Co-V2 positivity to the nasal-swab by reverse-transcriptase-polymerase chain- reaction (RT-PCR) assay tested by the local diagnostic laboratory * Age \>18 years * Presence of any symptoms suggestive of COVID-19, such as such as fever, fatigue, cough (with or without sputum production), shortness of breath, sore throat, nasal congestion, anorexia, malaise, or headache. Rarely, patients may also present with diarrhea, nausea, and vomiting * Presence of radiological findings of pneumonia assessed by chest radiograph, computed tomography * Moderate and severe COVID-19 as per previous definition national guideline/WHO * Give informed written consent Exclusion Criteria: * Absolute lymphocyte count \<500/mm3 and absolute neutrophil count of \<1000/mm3 and Hemoglobin 8gm/dl or less * Severe hepatic or renal impairment * Live vaccine within 3 months prior to first dose of the drug * Pregnancy * Lactation * Current malignancy or history of malignancies over the previous 5 years and/or history of malignancies in first degree relatives * Transaminases values 5-fold higher than the upper normal limit * Proven evidence of concomitant bacterial infections * Clinical evidences suggestive of pulmonary tuberculosis, or past history and/or history of contact with TB patient * Known hypersensitivity to Baricitinib * Those who have received Tocilizumab previously